Autolus Therapeutics
AUTL
73 hedge funds and large institutions have $272M invested in Autolus Therapeutics in 2021 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 10 closing their positions.
232% more call options, than puts
Call options by funds: $754K | Put options by funds: $227K
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
66% more capital invested
Capital invested by funds: $164M → $272M (+$108M)
37.65% more ownership
Funds ownership: 34.47% → 72.12% (+38%)
24% more funds holding
Funds holding: 59 → 73 (+14)
6% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
+$108M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$6.85M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$5.63M |
| 4 |
BlackRock
New York
|
+$1.93M |
| 5 |
SG Americas Securities
New York
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.23M |
| 2 |
JP Morgan Chase
New York
|
-$3M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$1.16M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$977K |
| 5 |
Millennium Management
New York
|
-$799K |
AUTL Hedge Fund Activity: Q4 2021 in Review
73 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q4 2021, worth a combined $272M — up 66% from $164M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new AUTL positions and 10 closed out — a net gain of 14 holders — while 19 added to existing stakes and 18 trimmed.
The largest buyer was Blackstone Inc, opening a new position worth an estimated $108M. The largest seller was Citadel Advisors, cutting an estimated $4.23M.
- 73 institutional investors held Autolus Therapeutics (AUTL) as of Q4 2021, up from 59 in Q3 2021.
- Funds reported $272M of Autolus Therapeutics stock for Q4 2021, up 66% quarter-over-quarter.
- 24 funds opened new Autolus Therapeutics positions in Q4 2021 and 10 closed out, a net change of +14 holders.
- The largest Autolus Therapeutics buyer in Q4 2021 was Blackstone Inc, an estimated $108M added.
- The largest Autolus Therapeutics seller in Q4 2021 was Citadel Advisors, an estimated $4.23M sold.
Based on aggregated 13F filings for Q4 2021.